The ID1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T-lymphocyte leukemia line, designed to disrupt the ID1 gene. This heterogeneous pool avoids clonal selection and provides a cost-effective model for studying loss-of-function effects in T-cell biology and leukemogenesis. The CRISPR/Cas9-mediated gene disruption ensures effective ID1 protein depletion, enabling detailed functional investigations without artifacts from single-cell isolation.
Jurkat cells are an immortalized human T-cell leukemia line originally established from the peripheral blood of a 14-year-old male with acute lymphoblastic leukemia. They are extensively used to study T-cell receptor signaling, apoptosis, and HIV infection, and they retain a T-cell progenitor-like phenotype. Their rapid proliferation and well-characterized signaling networks make them an ideal platform for genetic manipulation and pharmacological studies.
ID1 encodes a helix-loop-helix protein that acts as a dominant-negative inhibitor of basic HLH transcription factors by sequestering E-proteins, including E12/E47 (TCF3), HEB (TCF12), and E2-2 (TCF4). This interaction prevents E-protein binding to E-box sequences and blocks transcription of differentiation-related genes. ID1 is transcriptionally activated by BMP and TGF-?? ligands through SMAD1/5/8, as well as by EGF, FGF, and IL-6/STAT3 signaling. Downstream, ID1 suppresses p21 (CDKN1A) and p16 (CDKN2A), while promoting expression of Bcl-2, Survivin (BIRC5), Sox2, and Oct4 (POU5F1), thereby enhancing proliferation, survival, and stemness. In Jurkat cells, ID1 knockout relieves E-protein inhibition, allowing re-activation of pro-differentiation and apoptotic transcriptional programs.
Overexpression of ID1 is common in T-cell acute lymphoblastic leukemia and contributes to maintenance of the leukemic state and resistance to differentiation. The ID1 knockout in Jurkat polyclonal cells provides a tractable model to examine how loss of ID1 restores E-protein-dependent gene expression, leading to cell cycle arrest and apoptosis. This system is particularly useful for dissecting BMP and TGF-?? pathway contributions to T-cell malignancy and for evaluating cancer stem cell properties. The polyclonal nature reflects diverse editing events, permitting study of dosage effects and clonal heterogeneity.
These cells are applicable in a variety of research contexts, including mechanistic studies of ID1 in leukemia maintenance, differentiation therapy screening, and identification of small-molecule ID1 inhibitors. They support pathway analysis using Western blotting for ID1 and E-proteins, RT-qPCR for p21 and Cyclin D1, flow cytometry for cell cycle (propidium iodide) and apoptosis (Annexin V), proliferation assays (MTT or BrdU), immunofluorescence for differentiation markers, and transcriptome-wide RNA-seq. Drug sensitivity assays can uncover ID1-dependent vulnerabilities. For additional information, please contact Ascent Research.
